News

John Lowry, the incumbent in this role, is leaving Catalent to pursue other opportunities, and the search for a replacement is now under way, the company said. Mr

Under the terms of the agreement, Daewoong will commercialize, subject to regulatory approval, Eurand’s novel extended-release (ER) formulation of the muscle relaxant cyclobenzaprine HCl in South Korea. Cyclobenzaprine

According to HealthExtras, Catalyst Rx successfully implemented AvMed’s 220,000 commercial lives and 20,000 Medicare lives effective July 1, 2008. AvMed provides access to health care coverage for large

The transaction is expected to close on or about August 5, 2008, subject to customary closing conditions. The offering will result in gross proceeds of approximately $11.8 million

The size of the offering was increased from the originally announced nine million shares. Incyte also granted the underwriters a 30-day option to purchase an additional 1.57 million

The Phase I study is a randomized, double-blind and placebo-controlled single ascending dose study in healthy volunteers to evaluate the compound’s safety, tolerability and pharmacokinetic profile after oral

Bio-Bridge Science (BGES) now controls 51% of the outstanding capital stock of the seller. The total cash purchase price for the shares is RMB6 million. Liang Qiao, chairman

The headquarters, which will be led by CEO Vito Mangiardi, operates as the company’s corporate hub to drive growth in Bilcare’s American, European, and Asian regions. Dr Mangiardi

The data indicate that PYY did not meet the primary efficacy endpoint of a dose response of weight loss versus PYY dose, nor did PYY meet the secondary